<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        209-11-81
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1981
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        METHERGINE 0.2MG-ML AMPULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHYLERGONOVINE MALEATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G02AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>- What Methergin is</strong></p><p>Methergin is available as coated tablets and solution for injection in ampoules.</p><p>Methylergometrine is a semi-synthetic derivative of the naturally- occurring ergot alkaloid ergometrine. This medicine works by causing the muscle of the uterus to contract.</p><p><strong>- What Methergin is used for</strong></p><p>Methergin is used in obstetrics:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For the active management of the third stage of labor (as a means to promote separation of the placenta and to reduce blood loss).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To improve uterine tone and to control bleeding occurring during and after the third stage of labor, in association with Cesarean section or following abortion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To treat incomplete involution of the uterus, lochiometra (distended uterus due to mucus, blood and tissue debris that cannot be eliminated) and bleeding after birth.</p><p>Methergin must not be used for induction or enhancement of labor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not take Methergin:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are allergic</strong> (hypersensitive) to methylergometrine, to ergot alkaloids or any of the other ingredients of Methergin listed at the beginning of this leaflet.</p><p>If you think you may be allergic, ask your doctor for advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are in the first or second stage of the labor (before delivery of the anterior shoulder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe increase in blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a condition known as pre-eclampsia or eclampsia (characterized by high blood pressure, edema, presence of protein in urine and convulsions).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an occlusive vascular disease, including coronary heart disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an infection (e.g. childbed fever).</p><p>If any of these conditions apply to you, tell your doctor without taking Methergin.</p><p>b. Take special care with Methergin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a mild or moderate increase in blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have heart disease (particularly the ones affecting arteries that are connected to the heart) or if you are at risk of heart disease (for example: smoking, obesity, diabetes, high cholesterol).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an impaired liver or kidney function.</p><p>If any of these apply to you, tell your doctor before you take Methergin.</p><p>&nbsp;</p><p>&nbsp;</p><p>c. Taking other medicines</p><p><strong>Tell your doctor or pharmacist </strong>if you are taking or have recently taken any other medicines. Remember also those not prescribed by a doctor.</p><p>It is especially important that your doctor knows if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated for an infection with medicines called macrolide antibiotics such as erythromycin, clarithromycin, troleandomycin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated for HIV/AIDS with medicines such as ritonavir, nelfinavir, indinavir or delavirdine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated for fungal infection with medicines such as ketoconazole, itraconazole or voriconazole.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with medicines that constrict blood vessels including the ones used to treat migraine such as sumatriptan or the ones containing ergot alkaloids such as ergotamine or the ones called beta blockers. Methergin may enhance their effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with bromocriptine (a drug used to inhibit lactation). Its concomitant use with Methergin is not recommended.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with medicines called prostaglandins which are also used to contract the uterine muscle. Methergin may enhance their effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with glyceril trinitrate or any other drugs used to treat angina pectoris. Methergin may reduce the effect of these medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are being treated with medicines that are CYP3A inducers such as nevirapine or rifampicine. They may decrease the effect of Methergin.</p><p>Some anesthetics may decrease the potency of Methergin.</p><p>d. Methergin and older people</p><p>Methergin is not intended to be used in elderly patients.</p><p>e. Methergin and children</p><p>Methergin is not intended to be used in children. Some accidental administration to newborns was reported which sometimes had serious consequences.</p><p>f. Pregnancy and breast-feeding</p><p>Pregnant women</p><p>Methergin must not be administered to pregnant women.</p><p>Your doctor will discuss with you the potential risk of taking Methergin during pregnancy.</p><p>Breast-feeding mothers</p><p>Methergin passes into the breast milk and is not recommended during breast-feeding.</p><p>Your doctor will discuss with you the potential risk of taking Methergin during breast-feeding. The recommendation is not to breast-feed and to discard any milk secreted during the period when Methergin is used and at least 12 h after the last administration.</p><p>g. Driving and using machines</p><p>Methergin may cause dizziness and convulsions, therefore you should be particularly careful when driving or operating machines.</p><p>h. Information about some of the ingredients of Methergin</p><p>Methergin tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking Methergin tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow your doctor&rsquo;s instructions carefully. Do not exceed the recommended dosage. You should check with your doctor, health care provider or pharmacist if you are not sure.</p><p>Take your medicine exactly as your doctor tells you. Do not change the dose or stop treatment without talking to your doctor.</p><p>How much to take</p><p>For active management of third stage of labor or to improve uterine tone and control bleeding, injection into a muscle (i.m.) is the preferred way of administering Methergin.</p><p><strong><em>Active management of the third stage of labor:</em></strong> 1&nbsp;mL (0.2 mg) injected into a muscle or<em> </em>0.5 to 1 mL (0.1 to 0.2 mg) slowly injected into the vein, following delivery of the baby&rsquo;s shoulder or, at the latest, immediately after delivery of the baby.</p><p>For delivery under general anesthesia, the recommended dose is 1 mL (0.2 mg) slowly injected into the vein.</p><p><strong><em>Improvement of uterine tone and control of bleeding</em></strong><em>:</em><em> </em>1 mL (0.2 mg) injected into the muscle or 0.5 to 1 mL (0.1 to 0.2 mg) slowly injected into the vein. It may be repeated every 2-4&nbsp;hours if necessary, up to five doses within 24 hours.</p><p>Treatment of incomplete involution, lochiometra and bleeding after birth:<em> </em>0.125 to 0.25 mg orally (1 or 2 tablets), or 0.5 to 1 mL (0.1 to 0.2 mg) injected under the skin or into the muscle, up to 3&nbsp;times daily and usually for up to 5 days.</p><p>Injection into a muscle (i.m.) is preferable to injection into the vein (i.v.). Injections into the vein must be given slowly over a period of no less than 60&nbsp;seconds with careful monitoring of blood pressure. Intraarterial or periarterial injection must be avoided.</p><p>a. If you forget to take Methergin</p><p>If you miss a dose, do not take the missed dose at all and do not double the next dose. Instead, go back to your regular dosing schedule.</p><p>b. If you take more Methergin than you should</p><p>The symptoms of overdose are: nausea, vomiting, increased blood pressure, decreased blood pressure, numbness, tingling and pain in the extremities, respiratory depression, seizures, loss of consciousness.</p><p>If you have accidentally taken too much Methergin, talk to your doctor straight away. You may require medical attention.</p><p>If you have any further questions on the use of this product, ask your doctor, health care provider or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>As with all medicines, patients treated with Methergin may experience side effects, although not everybody gets them.</p><p>Side effects may occur with certain frequencies, which are defined as follows:</p><p>&nbsp;</p><p>Some side effects could be serious</p><p><strong>Some side effects are</strong><strong> uncommon</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; convulsions (fits)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p><strong>Some side effects are</strong><strong> rare</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; numbness, tingling of the fingers or toes and pale or cold hands or feet (signs of arterial spasms, vasospasms or vasoconstriction).</p><p><strong>Some side effects are</strong><strong> very rare</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unexplained shortness of breath, crushing chest pain or clouding of consciousness (signs of myocardial infarction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; signs of allergy such as a rapid fall in blood pressure, generalised reddening and/or swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; local swelling, redness, pain due to clotting of a vein (symptoms of thrombophlebitis)</p><p><strong>The frequency of some side effects is not known</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness or paralysis of limbs or face, difficulty speaking (signs of cerebrovascular accident)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; angina pectoris with symptoms such as crushing chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe irregular heart beat (signs of atrioventricular block)</p><p>If you experience any of these, <strong>tell your doctor straight away</strong>.</p><p>Some side effects are common</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abdominal pain</p><p>Some side effects are uncommon</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sweating</p><p>Some side effects are rare</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; slow heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; throbbing heartbeat</p><p>Some side effects are very rare</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ringing in the ears</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nasal congestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle cramp</p><p>If any of these affects you severely, tell your doctor.</p><p>If you notice any other side effects not mentioned in this leaflet, please inform your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>&nbsp;</em>Methergin coated tablets: store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methergin solution for injection (ampoules): protect from light; store in a refrigerator (2-8&deg;C); protect from freezing; the ampoules may be stored for 14 days out of a refrigerator but not above 25&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Methergin after the expiry date shown on the box. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Methergin coated tablets</p><p>One coated tablet contains 0.125&nbsp;mg methylergometrine hydrogen maleate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong><em>active substance</em> </strong>of Methergin coated tablets is methylergometrine hydrogen maleate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong><em>other ingredients</em></strong> are: maleic acid, stearic acid, gelatin, talc, maize starch, lactose, iron oxide red (E172), silicica colloidal, acacia, sucrose and cetyl palmitate.</p><p>Methergin solution for injection</p><p>Solution for injection (ampoule): 1&nbsp;mL contains 0.2&nbsp;mg methylergometrine hydrogen maleate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>active substance </strong>of Methergin solution for injection is methylergometrine hydrogen maleate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The <strong>other ingredients </strong>are: maleic acid, sodium chloride and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                .
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Approved by Novartis Pharmaceutical Company on 01/2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو مثرجين</strong></p><p dir="RTL">يتوافر مثرجين في شكل أقراص مغلَّفة وفي شكل محلول في أمبولات للإعطاء بالحقن.</p><p dir="RTL">ميثيل إرجومترين هو مشتق نصف تخليقي من قلواني الإرجوت الطبيعي إرجومترين. يعمل هذا الدواء بأن يجعل عضلة الرحم تنقبض.</p><p dir="RTL"><strong>ما هي استعمالات مثرجين</strong></p><p dir="RTL">يُستعمَل مثرجين في مجال التوليد:</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>للعلاج النشط للمرحلة الثالثة من الولادة (كطريقة لتحفيز انفصال المشيمة وتقليل فقدان الدم).</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لتحسين توتر الرحم وللسيطرة على النزف الذي يحدث أثناء المرحلة الثالثة من الولادة وبعدها، بالارتباط بالعمليات القيصرية أو عقب الإجهاض.</p><p dir="RTL"><strong>●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لعلاج النكوص غير الكامل للرحم، وتوسُّع الرحم بالهلابة (توسع الرحم بسبب المخاط والدم وبقايا الأنسجة التي لا يمكن التخلص منها)، والنزف بعد الولادة.</p><p dir="RTL">لا ينبغي استعمال مثرجين لتحريض الولادة أو لتشديدها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ. لا تستعملي مثرجين:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت لديك أرجية</strong> (حساسية مفرطة) تجاه ميثيل إرجومترين، أو قلوانيات الإرجوت، أو أي من المكونات الأخرى في مثرجين المذكورة في بداية هذه النشرة.</p><p dir="RTL">إذا ظننت أن لديك أرجية، استشيري طبيبك.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ في المرحلة الأولى أو الثانية من الولادة (قبل خروج الكتف الأمامي للمولود).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ارتفاع شديد في ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تعانين من حالة تُسمى مقدمة الارتعاج أو الارتعاج (وهي حالة تتصف بارتفاع ضغط الدم، والوذمة، ووجود بروتين في البول، وحدوث تشنجات).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض وعائي انسدادي، يشمل المرض القلبي التاجي.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك عدوى (مثلاً حمى المخاض).</p><p dir="RTL">إذا انطبق عليك أي من هذه الأمور، أخبري طبيبك مع الامتناع عن أخذ مثرجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. يجب توخي الحذر الخاص مع </strong><strong>مثرجين</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديكِ ارتفاع طفيف أو متوسط في ضغط الدم.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك مرض في القلب (لا سيما الأمراض التي تصيب الشرايين المتصلة بالقلب) أو إذا كانت لديك مخاطرة بالإصابة بمرض قلبي (مثلاً: التدخين، البدانة، مرض السكر، ارتفاع الكولسترول).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ضعف في وظائف الكبد أو الكلى.</p><p dir="RTL">إذا انطبق عليك أي من هذه الأمور، أخبري طبيبك قبل أن تستعملي مثرجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ج. استعمال أدوية أخرى</strong></p><p dir="RTL"><strong>أخبري طبيبك أو الصيدلي</strong> إذا كنت تستعمل حالياً أو إذا كنت قد استعملت منذ فترة قصيرة أي أدوية أخرى، ويشمل ذلك الأدوية التي يتم الحصول عليها بدون تذكرة طبية.</p><p dir="RTL">من المهم على نحو خاص أن يعرف طبيبك إذا كنتِ تستعملين أي من الأدوية التالية:</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً للعدوى بأدوية تُسمى المضادات الحيوية من نوع الماكروليد مثل إريثرومايسين، كلاريثرومايسين، ترولياندومايسين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً لعدوى HIV/ الإيدز بأدوية مثل ريتونافير، نلفينافير، إندينافير، ديلافيردين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً للعدوى الفطرية بأدوية مثل كيتوكونازول، إيتراكونازول، فوريكونازول.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً بأدوية تعمل على انقباض الأوعية الدموية وتشمل أدوية علاج الصداع النصفي مثل سوماتريبتان، أو الأدوية المحتوية على قلوانيات الإرجوت مثل إرجوتامين، أو الأدوية المسماة بحاصرات البيتا. قد يؤدي مثرجين إلى تشديد مفعول هذه الأدوية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً باستخدام بروموكريبتين (دواء يُستعمَل لمنع إفراز اللبن). لا يوصَى باستعماله بالتزامن مع مثرجين.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً بأدوية تُسمى بروستاجلاندين وهي تُستعمَل أيضاً لجعل عضلة الرحم تنقبض. قد يؤدي مثرجين إلى تشديد مفعولها.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً بجليسريل تراينيترات أو أي أدوية أخرى تُستخدَم لعلاج الذبحة الصدرية. قد يؤدي مثرجين إلى تقليل مفعول هذه الأدوية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ تتلقين علاجاً بأدوية محرضة لإنزيم CYP3A مثل نيفيرابين أو ريفامبيسين. فهي قد تؤدي إلى تقليل مفعول مثرجين.</p><p dir="RTL">بعض أدوية التخدير قد تقلل مفعول مثرجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>د. مثرجين والمسنات</strong></p><p dir="RTL">مثرجين غير مُصمَّم للاستعمال في المريضات المسنات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>هـ. مثرجين والأطفال</strong></p><p dir="RTL">مثرجين غير مُصمَّم للاستعمال في الأطفال. تم الإبلاغ عن بعض حالات تم فيها الإعطاء بطريق الخطأ للأطفال حديثي الولادة، والتي كانت لها أحياناً عواقب خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>و. الحمل والإرضاع</strong></p><p dir="RTL"><strong>النساء الحوامل</strong></p><p dir="RTL">لا ينبغي إعطاء مثرجين للنساء الحوامل.</p><p dir="RTL">سيناقش معك طبيبك المخاطر الممكنة التي قد تترتب على إعطائك مثرجين أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ز. الأمهات المرضعات</strong></p><p dir="RTL">ينفذ مثرجين إلى لبن الثدي ولا يوصَى باستعماله أثناء الإرضاع.</p><p dir="RTL">سيناقش معك طبيبك المخاطر الممكنة التي قد تترتب على إعطائك مثرجين أثناء الإرضاع. يوصَى بعدم الإرضاع من الثدي ويوصَى بالتخلص من اللبن الذي يتم إفرازه أثناء فترة استعمال مثرجين ولمدة 12 ساعة على الأقل بعد آخر استخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ح. قيادة السيارة وتشغيل الآلات</strong></p><p dir="RTL">قد يؤدي مثرجين إلى حدوث دوخة وتشنجات، لذلك يجب توخي الحذر الخاص عند قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ط. معلومات عن بعض المكونات في مثرجين</strong></p><p dir="RTL">تحتوي أقراص مثرجين على لاكتوز. إذا كان طبيبك قد أخبرك بأن لديك عدم تحمُّل لبعض أنواع السكر (مثل اللاكتوز)، اتصلي بطبيبك قبل أن تأخذي أقراص مثرجين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">التزمي بتعليمات طبيبك بكل دقة. لا تتجاوزي الجرعة الموصَى بها. إذا كنتِ غير متأكدة، راجعي طبيبكِ، الصيدلي أو مقدم الرعاية الصحية.</p><p dir="RTL">خذي دواءك بالضبط كما أوصاكِ طبيبك. لا تغيري الجرعة ولا توقفي العلاج بدون أن تتحدثي مع طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي الكمية التي ينبغي استعمالها</strong></p><p dir="RTL">للعلاج النشط للمرحلة الثالثة من الولادة أو لتحسين توتر الرحم وللسيطرة على النزف، الحقن في العضل هو الطريقة المفضلة لإعطاء مثرجين.</p><p dir="RTL"><strong><em>العلاج النشط للمرحلة الثالثة من الولادة</em></strong><em>:</em> 1 ملليلتر (0.2 مجم) يتم حقنها في العضل أو 0.5 إلى 1 ملليلتر (0.1 إلى 0.2 مجم) يتم حقنها ببطء في الوريد، عقب خروج كتف المولود أو على الأكثر فوراً بعد ولادة الطفل.</p><p dir="RTL">للولادة تحت التخدير العام، الجرعة الموصى بها هي 1 ملليلتر (0.2 مجم) يتم حقنها ببطء في الوريد.</p><p dir="RTL"><strong><em>تحسين توتر الرحم والسيطرة على النزف:</em></strong> 1 ملليلتر (0.2 مجم) يتم حقنها في العضل أو 0.5 إلى 1 ملليلتر (0.1 إلى 0.2 مجم) يتم حقنها ببطء في الوريد. يمكن تكرار ذلك كل 2-4 ساعات إذا لزم الأمر، حتى 5 جرعات خلال 24 ساعة.</p><p dir="RTL">علاج النكوص غير الكامل للرحم، وتوسُّع الرحم بالهلابة والنزف بعد الولادة: 0.125 إلى 0.25 مجم بالفم (1 أو 2 قرص)، أو 0.5 إلى 1 ملليلتر (0.1 إلى 0.2 مجم) يتم حقنها تحت الجلد أو في العضل، حتى 3 مرات يومياً وعادةً حتى 5 أيام.</p><p dir="RTL">الحقن في العضل مفضَّل على الحقن في الوريد. الحقن في الوريد يجب أن يُعطَى ببطء على مدى فترة لا تقل عن 60 ثانية مع المراقبة الدقيقة لضغط الدم. يجب تجنب الحقن في الشريان أو حول الشريان.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أ. إذا نسيت أن تأخذي مثرجين</strong></p><p dir="RTL">إذا نسيتِ إحدى الجرعات، تغاضي تماماً عن الجرعة المنسية ولا تضاعفي الجرعة التالية، وإنما عودي إلى نظامك المعتاد في تلقي الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ب. إذا أخذت مثرجين بأكثر مما ينبغي</strong></p><p dir="RTL">أعراض تجاوز الجرعة هي: غثيان، قيء، ارتفاع ضغط الدم، انخفاض ضغط الدم، خدر ووخز وألم في الأطراف، هبوط تنفسي، تشنجات، غياب عن الوعي.</p><p dir="RTL">إذا أخذت مثرجين بأكثر مما ينبغي على سبيل الخطأ، تحدثي فوراً مع طبيبك، فإنك قد تحتاجين إلى رعاية طبية.</p><p dir="RTL">إذا كانت لديكِ أسئلة أخرى عن استعمال هذا الدواء، إسألي طبيبكِ، مقدم الرعاية الصحية أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شأنه شأن جميع الأدوية، فإن المريضات اللاتي يستعملن مثرجين قد يتعرضن لحدوث آثار جانبية، غير أنها لا تحدث لجميع الأشخاص.</p><p dir="RTL">قد تحدث الآثار الجانبية بمعدلات حدوث معيَّنة ويتم تعريفها كما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الآثار الجانبية قد تكون خطيرة</strong></p><p dir="RTL"><strong>بعض الآثار الجانبية تكون غير شائعة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات (نوبات)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون نادرة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر، تنميل في أصابع اليدين أو القدمين وشحوب أو برودة في اليدين أو القدمين (علامات تدل على تشنجات شريانية، أو تشنجات وعائية، أو انقباض وعائي).</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون نادرة جداً</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس غير معروف السبب، ألم ساحق في الصدر أو تعتُّم الوعي (علامات تدل على احتشاء عضلة القلب)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات الأرجية مثلاً في شكل انخفاض سريع لضغط الدم، احمرار و/أو تورم عمومي</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هلاوس</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم موضعي، احمرار، ألم بسبب جلطة في أحد الأوردة (أعراض الالتهاب الوريدي التجلطي)</p><p dir="RTL"><strong>بعض الآثار الجانبية معدل حدوثها غير معروف</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف أو شلل في الأطراف أو في الوجه، صعوبة في الكلام (علامات الحادث الوعائي الدماغي)</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ذبحة صدرية مع أعراض مثل حدوث ألم ساحق في الصدر</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل شديد في انتظام ضربات القلب (علامات الإحصار الأذيني البطيني)</p><p dir="RTL">إذا حدث لديك أي من هذه الأمور، <strong>أخبري طبيبك فوراً</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون شائعة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بطني</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون غير شائعة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون نادرة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء ضربات القلب</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسرع ضربات القلب</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خفقان في ضربات القلب</p><p dir="RTL"><strong>بعض الآثار الجانبية تكون نادرة جداً</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طنين في الأذنين</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الأنف</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات عضلية</p><p dir="RTL">إذا حدثت لديك إصابة شديدة بأي من هذه الآثار، أخبري طبيبك.</p><p dir="RTL">إذا لاحظت أي آثار جانبية أخرى غير مذكورة في هذه النشرة، برجاء أن تخبري طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5-&nbsp; تخزين </strong><strong>مثرجين</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثرجين أقراص مغلَّفة: تُحفَظ في درجة حرارة أقل من 30&deg;م.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثرجين محلول للإعطاء بالحقن (أمبولات): يُحفَظ بعيداً عن الضوء؛ يُحفَظ في الثلاجة (2-8&deg;م)؛ لا ينبغي تجميده في الفريزر؛ يمكن حفظ الأمبولات لمدة 14 يوماً خارج الثلاجة على ألا تزيد درجة الحرارة عن 25&deg;م.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي استعمال مثرجين بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفَظ في عبوته الأصلية.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ بعيداً عن مرأى ومتناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مثرجين أقراص مغلَّفة</strong></p><p dir="RTL">يحتوي القرص المغلَّف الواحد على 0.125 مجم ميثيل إرجومترين هيدروجين ماليات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة</strong> في مثرجين أقراص مغلَّفة هي ميثيل إرجومترين هيدروجين ماليات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي: حمض مالييك، حمض ستياريك، جيلاتين، تلك، نشا ذرة، لاكتوز، أكسيد الحديد الأحمر (E172)، سيليكا غروانية، أكاسيا، سيكروز، سيتيل بالميتات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مثرجين محلول للإعطاء بالحقن</strong></p><p dir="RTL">محلول للإعطاء بالحقن (أمبولات): يحتوي 1 ملليلتر على 0.2 مجم ميثيل إرجومترين هيدروجين ماليات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المادة الفعالة</strong> في مثرجين محلول للإعطاء بالحقن هي ميثيل إرجومترين هيدروجين ماليات.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي: حمض مالييك، كلوريد صوديوم، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قبل شركة نوفارتس للأدوية في 01/2015 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                METHERGIN 0.2 mg/ml injectable solution 
METHERGIN 0.125 mg coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                METHERGIN 0.2 mg/ml injectable solution
1 ml of injectable solution contains:
Active ingredient
methylergometrine maleate acid .................................................... 0.20 mg

METHERGIN 0.125 mg coated tablets
One coated tablet contains:
Active ingredient
methylergometrine maleate acid ................................................... 0.125 mg

Excipients:
Lactose monohydrate, sucrose

For a full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injectable solution. 
Coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Active treatment of the third stage of childbirth (placenta delivery) &ndash; in order to promote the detachment of the placenta and reduce hemorrhaging.</p><p>Treatment of uterine atonia and hemorrhaging during and after placental delivery in the case of a cesarean section or after an abortion.</p><p>Treatment of uterine subinvolution, lochiometra, delayed puerperal hemorrhaging.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><u>General population</u></p><p><em>Active treatment of placental delivery:</em></p><p>The intramuscular (IM) is the recommended route of administration. When administered intravenously (IV), the dose should be injected slowly over a period of not less than 60 seconds (see section 4.4).</p><p>The recommended dosage of Methergin is: 1 ml (0.2 mg) im or from 0.5 to 1 ml (0.1 to 0.2 mg) injected by slow intravenous administration after successful disengagement of the front shoulder or, at the latest, immediately after the escape of the fetus. The expulsion of the placenta, which usually comes off the first contraction induced by violent Methergin, should be manually facilitated through pressure exerted on the bottom of the uterus.</p><p>In case of delivery under general anesthesia, the recommended dose is 1 ml (0.2 mg) with a slow intravenous injection.</p><p><em>Treatment of uterine atonia/hemorrhaging:</em></p><p>The intramuscular (IM) is the recommended route of administration. When administered intravenously (IV), the dose should be injected slowly over a period of not less than 60 seconds (see section 4.4).</p><p>The recommended dosage of Methergin is: 1 ml (0.2 mg) im or 0.5 to 1 ml (0.1 to 0.2 mg) injected by slow intravenous administration (see section 4.4). If necessary, the administration can be repeated every 2-4 hours up to a maximum of 5 doses within 24 hours.</p><p><em>Treatment of uterine subinvolution, lochiometra, delayed puerperal hemorrhaging:</em></p><p>The recommended dosage of Methergin is: 1 or 2 tablets (0.125 to 0.25 mg) orally, or from 0.5 to 1 ml (0.1 to 0.2 mg) im up to 3 times a day and usually up to 5 days Administer 0.125-0.25 mg orally (1 or 2 tablets) or 0.5-1 ml (0.1-0.2 mg) intramuscularly up to three times a day.</p><p><u>Special Populations</u></p><p><u>Renal / hepatic impairment</u></p><p>In the presence of impaired hepatic or renal impairment (see section 4.4), we must exercise caution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Hypersensitivity to the active substance, to other ergot alkaloids, or to any of the excipients listed in section 6.1.
- Pregnancy (see section 4.6)
- Dilatation phase of childbirth; second stage of childbirth before the engagement of the head (Methergin should not be used to induce or accelerate labour)
- Severe hypertension;
- Pre-eclampsia and eclampsia;
- Vessel obliterating diseases (including cardiac ischemia); 
- Sepsis.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General recommendations on the administration</u></p><p>For breech and other abnormal presentations, Methergin should not be given before the complete discharge of the fetus and multiple births not before the release of the last fetus.</p><p>Active treatment of the third stage of labor requires supervision midwife. The intramuscular injection is the recommended route of administration. Intravenous injections should be made slowly over a period of not less than 60 seconds, with careful monitoring of blood pressure.</p><p>You should avoid injections intra-or peri-arterial.</p><p><u>Breastfeeding</u></p><p>During breast-feeding are possible side effects for the baby and the reduction of milk secretion. Women should not breast-feed during treatment with Methergin and at least 12 hours after the last dose. The milk secreted during this period should be eliminated (see section 4.6).</p><p><u>Hypertension and hepatic or renal impairment</u></p><p>Use with caution in the presence of mild or moderate hypertension (severe hypertension is a contraindication) or in patients with hepatic or renal impairment.</p><p><u>Coronary artery disease</u></p><p>The patients with coronary artery disease or with risk factors for coronary artery disease (eg. Smoking, obesity, diabetes, hypercholesterolemia) can be more susceptible to the development of myocardial ischemia and infarction associated with vasospasm induced by methylergometrine (see section 4.8).</p><p><u>Medication errors</u></p><p>It has been reported accidental administration to infants. In these cases of accidental overdose have been reported in the newborn symptoms such as shortness&nbsp; of&nbsp; breath,&nbsp; convulsions,&nbsp; cyanosis,&nbsp; oliguria&nbsp; and&nbsp; peripheral vasocostriction. Furthermore, encephalopathy has been reported in infants presenting with signs and symptoms such as irritability, agitation and lethargy. Treatment should be symptomatic, and in severe cases it was necessary to support the respiratory and cardiovascular systems. In the absence of adequate treatment have been reported fatal cases (see section 4.9).</p><p>The patient should be informed to store the medicine separately from other medicines to be administered to neonates.</p><p><u>Interactions</u></p><p>The ergot alkaloids are substrates of CYP3A4. Concomitant use of Methergin with&nbsp; potent&nbsp; CYP3A4&nbsp; inhibitors&nbsp; such&nbsp; as&nbsp; macrolide&nbsp; antibiotics&nbsp; (eg. Troleandomycin, erythromycin, clarithromycin) or protease inhibitors of HIV reverse transcriptase (eg. Ritonavir, indinavir, nelfinavir, delavirdine) or azolinici antifungals (eg. ketoconazole, itraconazole, voriconazole), should be avoided, as this may result in exposure to high methylergometrine and then ergot toxicity (vasospasm and ischemia of the extremities and other tissues) (see section 4.5).</p><p>It is not recommended the concomitant use of Methergin with bromocriptine during puerperium and prostaglandins (see section 4.5).</p><p>Caution must be exercised in the concomitant use of Methergin with less potent CYP3A4 inhibitors (eg. Cimetidine, delavirdine, grapefruit juice, quinupristin, dalfopristin), or drugs with vasoconstrictor / vasopressor such as the triptans (5HT1B receptor agonists / 1D), the sympathomimetics, or other ergot alkaloids or beta-blockers (see section 4.5).</p><p><u>Important information about some of the ingredients</u></p><p>Methergin 0.125 mg coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or malabsorption of glucose / galactose malabsorption should not take this medicine. Methergin 0.125 mg coated tablets contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase- isomaltase insufficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ergot alkaloids are substrates of CYP3A4</p><p><u>Interactions resulting from concomitant use not recommended</u></p><p><u>Inhibitors of CYP3A4</u></p><p>The concomitant use of Methergin and potent CYP3A inhibitors, such as macrolide antibiotics (e.g.: troleandomycin, erythromycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g..: ritonavir, indinavir, nelfinavir, delavirdine), or azoline antimycotics (e.g..: ketoconazole, itraconazole, voriconazole), should be avoided because it could cause highed methlergometrine exposure and therefore ergot toxicity (vasospasms and ischemia of the extremities and other tissues) (see section 4.4).</p><p><u>Bromocriptine</u></p><p>Concomitant use of bromocriptine and Methergin during the puerperium is not recommended as the methylergometrine may increase the effect of other vasoconstrictive ergot alkaloids (see section 4.4).</p><p><u>Prostaglandins</u></p><p>Prostaglandins (eg. sulprostone, dinoprostone, misoprostol) facilitate the contraction of the myometrium, and Methergin may potentiate the action of prostaglandins on the uterus and vice versa. Concomitant use with these drugs is not recommended (see section 4.4).</p><p><u>Interactions to take into account</u></p><p><u>Less potent CYP3A4 inhibitors</u></p><p>Caution is required when Methergin is used together with less potent CYP3A inhibitors (eg. cimetidine, delavirdine, grapefruit juice, quinupristin, dalfopristin), as it can produce a highed exposure to methylergometrine.</p><p><u>Vasoconstrictors, triptans, sympathomimetics and other ergot alkaloids</u></p><p>Caution is required when Methergin is used simukltaneously with other vasoconstrictors or ergot alkaloids. Methylergometrine can increase the vasoconstrictive/vasopressor effects of other drugs such as the tryptanes (agonists of the 5HT1B/1D receptor), sympathomimetics (including those present in local anesthetics), or other ergot alkaloids (see section 4.4).</p><p><u>Beta-blockers</u></p><p>Caution must be exercised when Methergin is used simultaneously with beta- blockers. Co-administration of beta-blockers may potentiate the action of vasoconstrictive ergot alkaloids (see section 4.4).</p><p><u>Anesthetics</u></p><p>Anesthetics such as halothane and methoxyflurane may reduce the power of oxytocic Methergin (see section 4.2).</p><p><u>Inducers of CYP3A4</u></p><p>It is probable that drugs potent CYP3A4 inducers (eg.&nbsp; nevirapine, rifampin) reduce the pharmacologic action of Methergin.</p><p><u>Glyceryl trinitrate and other antianginal drugs</u></p><p>The methylergometrine caises vasoconstriction and can reduce the effect of glyceryl trinitrate and other antianginal drugs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>The use of Methergin during pregnancy is contraindicated because of its potent uterotonic activity.</p><p><u>Lactation</u></p><p>It was reported that methylergometrine reduces milk secretion and is excreted in breast milk (see paragraphs 5.1-5.2). Have been isolated cases of intoxication in breast-fed infants whose mothers had taken the drug for several days. Were observed (and then disappeared after discontinuation of treatment) one or more of the following symptoms: increased blood pressure, tachycardia or bradycardia, vomiting, diarrhea, agitation and seizures.</p><p>In view of possible side effects for the baby and the reduction of milk production, we do not recommend the use of Methergin during lactation.</p><p>Women should not breast-feed during treatment with Methergin and for at least</p><p>12 hours after the last dose. The milk secreted during this period should be eliminated (see section 4.4).</p><p><u>Fertility</u></p><p>There are no data on fertility in light of the current indications of the product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methylergometrine can cause dizziness and convulsions. It is therefore necessary to pay particular attention when driving vehicles or using machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions (table 1) are listed by system organ classes in MedDRA. Within each system-organ class, adverse reactions are ranked by frequency, the most frequent reactions first. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. In addition, for each reaction is also given the category corresponding frequency using the following convention (CIOMS III):&nbsp; &nbsp;very common (&ge;1/10); common (&ge;1/100, &lt;1/10); uncommon (&ge;1/1000, &lt;1/100); rare (&ge;1/10.000, &lt;1/1000); very rare (&lt;1/10.000),not known (the frequency cannot be established on the basis of available data).</p><p>&nbsp;</p><p><u>T</u><u>able 1</u></p><table border="2" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><strong>Immune system alterations</strong></td></tr><tr><td style="vertical-align:top">Very rare</td><td style="vertical-align:top">Anaphylactic&nbsp;reactions</td></tr><tr><td colspan="2" style="vertical-align:top"><strong>Nervous&nbsp;system alterations</strong></td></tr><tr><td style="vertical-align:top">Common</td><td style="vertical-align:top">Headache</td></tr><tr><td style="vertical-align:top">Uncommon</td><td style="vertical-align:top">Dizziness,&nbsp;convulsions</td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hallucinations</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Alterations affecting the ear and labyrinth</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Chest pain</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bradycardia, tachycardia, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>myocardial infarction, coronary artery spasm</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Vasoconstriction, vasospasm, arterial spasm (peripheral)</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Thrombophlebitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nasal congestion</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Alterations affecting the gastrointestinal apparatus</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nausea, vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Diarrhea</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue alterations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Skin eruptions</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Hyperhidrosis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Alterations affecting the skeletal muscle and connective tissue apparatus</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>P</strong><strong>regnancy, puerperium and perinatal conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain (caused by the uterine contractions)</p></td></tr></tbody></table><p><strong><u>Adverse reactions from post-marketing spontaneous reports and literature cases</u></strong></p><p><strong><u>(frequency not known)</u></strong></p><p>Because these reactions are reported voluntarily from a population of uncertain abundance, it is not possible to reliably estimate their frequency which is then categorized as not known. Adverse reactions are listed by system organ classes in MedDRA. &nbsp;Within each class, adverse reactions are arranged in order of decreasing seriousness.</p><p><u>Ne</u><u>rvous system disorders</u></p><p>Cerebrovascular accident, paraesthesia.</p><p><u>Cardiac disorders</u></p><p>Ventricular fibrillation, ventricular tachycardia, angina pectoris, atrioventricular block.</p><p>&nbsp;</p><p><strong>--<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>--Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>--Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><p>-- Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Symptoms:</em></strong> Nausea; vomiting; hypertension or hypotension; numbness, pins and needles and pain in the extremities; respiratory depression; convulsions; coma.</p><p><strong><em>Treatment:</em></strong> Eliminate the drug ingested orally by administering high doses of active carbon.</p><p>Symptomatic&nbsp;&nbsp;&nbsp; treatment&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; careful cardiovascular&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; respiratory monitoering. If sedation is required, the benzodiazepines can be used.</p><p>In&nbsp; the&nbsp; case&nbsp; of&nbsp; arterial&nbsp; spasm,&nbsp; a&nbsp; vasodilator&nbsp; such&nbsp; as&nbsp; sodium&nbsp; nitroprusside, phentolamine or dihydralazine should be administered. In the case of coronary constriction, appropriate anti-anginal treatment (e.g. nitrates) should be given.</p><p><strong>Medication errors</strong></p><p>It has been reported accidental administration to infants.&nbsp; In these cases of accidental&nbsp; overdose&nbsp; in&nbsp; the&nbsp; neonate&nbsp; have &nbsp;been&nbsp; reported&nbsp; symptoms&nbsp; such&nbsp; as shortness&nbsp; of&nbsp; breath,&nbsp; convulsions,&nbsp; cyanosis,&nbsp; oliguria&nbsp; and&nbsp; peripheral vasocostriction. Furthermore, encephalopathy has been reported in infants presenting with signs and symptoms such as irritability, agitation and lethargy. Treatment should be symptomatic; in severe cases were required respiratory support and cardiovascular systems. In the absence of proper treatment, have been reported fatal cases (see section 4.4).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- <em>Pharmacotherapeutic group: oxytocics - Ergot alkaloids. ATC code: G02AB01.</em></p><p>&nbsp;<em>Mechanism of action:</em></p><p>Methylergometrine, a semi-synthetic derivate of the natural ergometrine alkaloid, is a potent and specific uterotonic agent.</p><p>It acts directly on the smooth musculature of the uterus by increasing its basal tone, and the frequency and amplitude of rythmic contractions. Its effects on the central nervous system and cardiovascular apparatus are less pronounced than those of other ergot alkaloids.</p><p>- <em>Pharmacodynamic effects. </em></p><p>The potent and selective oxytocic effect of methylergometrine is a result of its specific mechanism of action and as a partial agonist and antagonist of serotoninergic, dopaminergic and -adrenergic receptors. However, this does not completely preclude the possibility of complications due to vasoconstriction (see 4.8).</p><p>For the prevention and treatment of bleeding uterine by im injection, can be considered the association of Methergin and oxytocin, as oxytocin presents a very short latency period, while the methylergometrine possesses a prolonged duration of action.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methergin acts 30-60 seconds after administration, 2-5 minutes after administration, and 5-10 minutes after oral administration, and its duration of action is 4-6 hours.</p><p><strong><em>Absorption:</em></strong> Studies of fasting healthy female volunteers have shown that the oral absorption of a 0.2 mg tablet is quite rapid, and leads to mean peak plasma concentrations (Cmax) of 3243+1308 pg/ml in 1.12+0.82 hours (tmax). After the intramuscular injection of 0.2 mg, Cmax is 5918+1952 pg/ml andl tmax 0.41+0.21 hours. The bioavailability of the tablets is equivalent to that of the injectable solution administered orally, and is dose-dependent after the administration of 0.1, 0.2 and 0.4 mg.</p><p>After an intramuscular injection, absorption is 25% greater than after oral administration. Delayed gastrointestinal absorption has been observed in post- partum patients receiving continuous treatment with Methergin tablets (a tmax of about 3 hours).</p><p><strong><em>Distribution:</em></strong> After intravenous administration, methylergometrine is rapidly distributed from the plasma to the peripheral tissues within 2-3 minutes or even less. In healthy female volunteers distribution volume is 56.1+17.0 litres. It is not known whether the drug crosses the blood/brain barrier.</p><p><strong><em>Biotransformation:</em></strong> Methylergometrine is mainly metabolised in the liver. Its metabolic pathway has not been studied in humans. In vitro studies have shown the N-demethylation and hydroxylisation of the phenyl ring.</p><p><strong><em>Elimination:</em></strong>&nbsp;&nbsp; Plasma&nbsp;&nbsp; clearance in&nbsp;&nbsp; healthy&nbsp;&nbsp; female&nbsp;&nbsp; volunteers&nbsp;&nbsp; is&nbsp;&nbsp; 14.4+4.5 litres/hour, and the the mean elimination half-life is 3.29+1.31 hours. A study of male volunteers has shown that only 3% of an oral dose is eliminated as unchanged drug in urine. The methylergometrine is also excreted in breast milk. After 1 h after administration of a single dose of 250 micrograms of methylergonovine, the ratio of concentrations milk / plasma was 0.18 + 0.03. The half-life of methylergometrine reported in milk was 2.3 + 0.3 h.</p><p><strong><em>Linearity / non-linearity:</em></strong> The bioavailability of the tablet is shown to be proportional to the dose.</p><p><strong><em>Studies of bioavailability/bioequivalence:</em></strong>&nbsp; the bioavailability of the tablet is shown to be equivalent to that of the solution i.m. administered orally.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The genotoxic potential of methylergometrine has not been determined. There are no available studies that have evaluated the carcinogenic potential of methylergonovine. Have not been performed standard studies on fertility and reproductive toxicity in animals methylergometrine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>M</em></strong><strong><em>ETHERGIN 0.2 mg/ml injectable solution</em></strong></p><p>Maleic acid, sodium chloride, water for injectable preparations.</p><p><strong><em>M</em></strong><strong><em>ETHERGIN 0.125 mg coated tablets</em></strong></p><p>Maleic acid, gelatine, stearic acid, talc, maize starch, <strong>lactose monohydrate</strong>, red iron oxide, anhydrous colloidal silica, gum arabic, <strong>sucrose</strong>.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None &nbsp;known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Methergin 0.2 mg/ml injectable solution ……….. ............................... 4 years
Methergin 0.125 mg coated tablets…………....................................... 2 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Methergin 0.2 mg/ml injectable solution:</u></em></p><p>Store at a temperature of between 2&deg;C and 8&deg;C. Do not freeze.</p><p>Keep ampoules in the outer carton to protect against the light.</p><p>Do not store at a temperature of more 25&deg;C for longer than two weeks.</p><p><em><u>Methergin 0.125 mg coated tablets:</u></em></p><p>This medicine does not require any special storage conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>M</em></strong><strong><em>ETHERGIN 0.2 mg/ml injectable solution</em></strong></p><p>Glass ampoule - 5 ampoules of 1 ml</p><p>&nbsp;</p><p><strong><em>M</em></strong><strong><em>ETHERGIN 0.125 mg coated tablets</em></strong></p><p>Blister - 30 coated tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No particular instructions</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                01/2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>